Immunotherapy Treatment for Triple Negative Breast Cancer

Triple-negative breast cancer (TNBC) is considered one of the highest-risk subtypes of breast cancer and has dismal prognosis. Local recurrence rate after standard therapy in the early breast cancer setting can be upwards to 72% in 5 years, and in the metastatic setting, the 5-year overall survival...

Full description

Bibliographic Details
Published in:Pharmaceuticals
Main Authors: Elizabeth R. Berger, Tristen Park, Angeleke Saridakis, Mehra Golshan, Rachel A. Greenup, Nita Ahuja
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Subjects:
triple-negative breast cancer
immunotherapy
treatment algorithms
Online Access:https://www.mdpi.com/1424-8247/14/8/763

Internet

https://www.mdpi.com/1424-8247/14/8/763

Similar Items